2022
Childhood adversity and adulthood major depressive disorder
Zisook S, Planeta B, Hicks PB, Chen P, Davis LL, Villarreal G, Sapra M, Johnson GR, Mohamed S. Childhood adversity and adulthood major depressive disorder. General Hospital Psychiatry 2022, 76: 36-44. PMID: 35366613, DOI: 10.1016/j.genhosppsych.2022.03.008.Peer-Reviewed Original ResearchMeSH KeywordsAdultAdverse Childhood ExperiencesAnxiety DisordersDepressive Disorder, MajorFemaleHumansQuality of LifeSuicidal IdeationConceptsMajor depressive disorderChildhood adversityDepressive disorderSuicidal ideationLower remission rateLower depression severityDepression Outcomes studyMore lifetime episodesGOV IDENTIFIERRemission rateClinical featuresClinical outcomesSevere depressionTreatment strategiesLifetime episodesOutcome studiesDepression severitySwitching treatmentYounger ageSecondary analysisComorbid PTSDChildhood maltreatmentWorse qualitySpecific typesDisorders
2020
Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment‐resistant major depressive disorder: A VAST‐D report
Zisook S, Johnson G, Hicks P, Chen P, Beresford T, Michalets J, Rao S, Thase M, Wilcox J, Sevilimedu V, Mohamed S. Continuation phase treatment outcomes for switching, combining, or augmenting strategies for treatment‐resistant major depressive disorder: A VAST‐D report. Depression And Anxiety 2020, 38: 185-195. PMID: 33225492, DOI: 10.1002/da.23114.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsDepressive Disorder, MajorDepressive Disorder, Treatment-ResistantHumansQuality of LifeTreatment OutcomeConceptsDepressive symptom severityContinuation treatmentBupropion SRTreatment outcomesTreatment-resistant major depressive disorderSymptom severitySignificant differential treatment effectsContinuation treatment phaseAcute-phase treatmentAbnormal laboratory valuesLower relapse rateMajor depressive disorderQuality of lifeLess anxietyDifferential treatment effectsMore somnolenceDry mouthRelapse rateExtrapyramidal effectsFull remissionWeek 12Continuation phaseTreatment attemptsDepressive disorderLaboratory valuesStages of major depressive disorder and behavioral multi-morbidities: Findings from nationally representative epidemiologic study
Rhee TG, Mohamed S, Rosenheck RA. Stages of major depressive disorder and behavioral multi-morbidities: Findings from nationally representative epidemiologic study. Journal Of Affective Disorders 2020, 278: 443-452. PMID: 33010569, DOI: 10.1016/j.jad.2020.09.081.Peer-Reviewed Original ResearchMeSH KeywordsAdultComorbidityCross-Sectional StudiesDepressive Disorder, MajorDiagnostic and Statistical Manual of Mental DisordersEpidemiologic StudiesHumansMorbidityConceptsChronic major depressive disorderMajor depressive disorderNew-onset major depressive disorderOnset major depressive disorderBorderline personality disorderDepressive disorderUse disordersRepresentative cross-sectional surveyRepresentative epidemiologic studyPersonality disorderMore psychiatric disordersSubstance use disordersAlcohol use disorderNational Epidemiologic SurveyRelated Conditions-IIICross-sectional surveyDSM-5 diagnostic criteriaMultivariable analysisGroup of adultsEpidemiologic studiesUS adultsDiagnostic criteriaPsychiatric disordersEpidemiologic SurveyMDD historyImpact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial.
Mohamed S, Johnson GR, Sevilimedu V, Rao SD, Hicks PB, Chen P, Lauro K, Jurjus G, Pilkinton P, Davis L, Wilcox JA, Iranmanesh A, Sapra M, Aslam M, Michalets J, Thase M, Zisook S. Impact of Concurrent Posttraumatic Stress Disorder on Outcomes of Antipsychotic Augmentation for Major Depressive Disorder With a Prior Failed Treatment: VAST-D Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2020, 81 PMID: 32603560, DOI: 10.4088/jcp.19m13038.Peer-Reviewed Original ResearchConceptsConcurrent posttraumatic stress disorderMajor depressive disorderPosttraumatic stress disorderDepressive disorderVeterans Health Administration medical centersNonpsychotic major depressive disorderStress disorderMini International Neuropsychiatric InterviewAdequate antidepressant treatmentPoor overall outcomeDepressive Symptomatology-Clinician RatedSevere depressive symptomsAntipsychotic augmentationInitial remissionAntidepressant treatmentSuboptimal responseAntipsychotic aripiprazoleCurrent antidepressantsAntidepressant trialsQuick InventoryNeuropsychiatric InterviewClinical trialsMedical CenterRemissionDepressive symptoms
2019
General Predictors and Moderators of Depression Remission: A VAST-D Report
Zisook S, Johnson GR, Tal I, Hicks P, Chen P, Davis L, Thase M, Zhao Y, Vertrees J, Mohamed S. General Predictors and Moderators of Depression Remission: A VAST-D Report. American Journal Of Psychiatry 2019, 176: 348-357. PMID: 30947531, DOI: 10.1176/appi.ajp.2018.18091079.Peer-Reviewed Original ResearchMeSH KeywordsAdultAdverse Childhood ExperiencesAgedAged, 80 and overAntidepressive AgentsAripiprazoleBupropionDepressive Disorder, MajorDrug SubstitutionDrug Therapy, CombinationEmploymentFemaleGriefHumansLife TablesMaleMiddle AgedPrognosisQuality of LifeRemission InductionSeverity of Illness IndexSingle-Blind MethodUnited StatesUnited States Department of Veterans AffairsYoung AdultConceptsNext-step treatmentsRelease bupropionVeterans Health Administration patientsPatients' baseline featuresSingle-blind trialMajor depressive disorderDepression Outcomes studyComplicated grief symptomsAntidepressant treatmentBaseline characteristicsInitial treatmentDepression remissionDepressive disorderRemissionOutcome studiesTreatment selectionTreatment groupsHypomanic symptomsSwitching treatmentClinical imperativePositive mental healthChildhood adversityPatientsMental healthSpecific augmentation
2018
Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial.
Yoon J, Zisook S, Park A, Johnson GR, Scrymgeour A, Mohamed S. Comparing Cost-Effectiveness of Aripiprazole Augmentation With Other "Next-Step" Depression Treatment Strategies: A Randomized Clinical Trial. The Journal Of Clinical Psychiatry 2018, 80 PMID: 30695291, DOI: 10.4088/jcp.18m12294.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntidepressive Agents, Second-GenerationAripiprazoleBupropionCost-Benefit AnalysisDepressionDepressive Disorder, MajorDrug SubstitutionDrug SynergismDrug Therapy, CombinationFemaleHumansMaleMiddle AgedOutcome Assessment, Health CareRemission InductionUnited StatesUnited States Department of Veterans AffairsVeteransConceptsIncremental cost-effectiveness ratioStandard antidepressant therapyBupropion augmentationAripiprazole augmentationAntidepressant therapyClinical trialsVeterans Affairs Medical CenterDepression Outcomes trialMental health care costsRate of remissionRandomized clinical trialsHealth care sector perspectiveICD-9 codesTreatment of depressionCost-effectiveness ratioHealth care costsCost-effective relativeCost-effectiveness analysisOutcome trialsMean ageQuick InventoryDepression diagnosisTreatment strategiesRemissionMedical Center
2017
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial
Mohamed S, Johnson GR, Chen P, Hicks PB, Davis LL, Yoon J, Gleason TC, Vertrees JE, Weingart K, Tal I, Scrymgeour A, Lawrence DD, Planeta B, Thase ME, Huang GD, Zisook S, Rao S, Pilkinton P, Wilcox J, Iranmanesh A, Sapra M, Jurjus G, Michalets J, Aslam M, Beresford T, Anderson K, Fernando R, Ramaswamy S, Kasckow J, Westermeyer J, Yoon G, D’Souza D, Larson G, Anderson W, Klatt M, Fareed A, Thompson S, Carrera C, Williams S, Juergens T, Albers L, Nasdahl C, Villarreal G, Winston J, Nogues C, Connolly K, Tapp A, Jones K, Khatkhate G, Marri S, Suppes T, LaMotte J, Hurley R, Mayeda A, Niculescu A, Fischer B, Loreck D, Rosenlicht N, Lieske S, Finkel M, Little J. Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial. JAMA 2017, 318: 132-145. PMID: 28697253, PMCID: PMC5817471, DOI: 10.1001/jama.2017.8036.Peer-Reviewed Original ResearchConceptsMajor depressive disorderAcute treatment phaseDepressive disorderSwitch groupAdverse effectsTreatment phaseUS Veterans Health Administration medical centersVeterans Health Administration medical centersNonpsychotic major depressive disorderWeeks of treatmentEffects of antidepressantsLikelihood of remissionSignificant treatment differencesBupropion monotherapyRandomized patientsRemission rateBupropion groupSecondary outcomesPrimary outcomeAtypical antipsychoticsDifferent antidepressantsFirst antidepressantClinical trialsCurrent treatmentMedical Center
2016
Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report
Zisook S, Tal I, Weingart K, Hicks P, Davis LL, Chen P, Yoon J, Johnson GR, Vertrees JE, Rao S, Pilkinton PD, Wilcox JA, Sapra M, Iranmanesh A, Huang GD, Mohamed S. Characteristics of U.S. Veteran Patients with Major Depressive Disorder who require “next-step” treatments: A VAST-D report. Journal Of Affective Disorders 2016, 206: 232-240. PMID: 27479536, DOI: 10.1016/j.jad.2016.07.023.Peer-Reviewed Original ResearchConceptsMajor depressive disorderClinical featuresDepressive disorderNonpsychotic major depressive disorderInitial standard treatmentNon-veteran samplesU.S. veteran patientsCharacteristics of patientsSample of veteransRecent suicidal ideationPublic health imperativeLasting treatmentMDD treatmentVeteran patientsClinical onsetPsychiatric comorbidityAntidepressant trialsStandard treatmentClinical trialsDepression subtypesRecurrent depressionIndividual patientsSpecific treatmentPatientsSuicidal ideation
2015
The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations
Mohamed S, Johnson GR, Vertrees JE, Guarino PD, Weingart K, Young IT, Yoon J, Gleason TC, Kirkwood KA, Kilbourne AM, Gerrity M, Marder S, Biswas K, Hicks P, Davis LL, Chen P, Kelada A, Huang GD, Lawrence DD, LeGwin M, Zisook S. The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations. Psychiatry Research 2015, 229: 760-770. PMID: 26279130, DOI: 10.1016/j.psychres.2015.08.005.Peer-Reviewed Original Research
2010
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.
Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA. Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. The Journal Of Clinical Psychiatry 2010, 72: 75-80. PMID: 20868641, PMCID: PMC5052810, DOI: 10.4088/jcp.09m05258gre.Peer-Reviewed Original ResearchConceptsMajor depressive episodeSecond-generation antipsychoticsDSM-IV-defined schizophreniaCurrent major depressive episodeClinical practice recommendationsTrial of treatmentClinical practice guidelinesTreatment of depressionCalgary Depression ScaleClinical Antipsychotic TrialsSecond-generation drugsSymptoms of depressionPhase 1 analysisTardive dyskinesiaDepressive episodeChronic schizophreniaAntipsychotic TrialsPractice guidelinesDepression ScaleDepressive symptomsTreatment groupsBaseline scoresPatientsAntipsychoticsPractice recommendations
2009
Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs.
Mohamed S, Leslie DL, Rosenheck RA. Use of antipsychotics in the treatment of major depressive disorder in the U.S. Department of Veterans Affairs. The Journal Of Clinical Psychiatry 2009, 70: 906-12. PMID: 19422760, DOI: 10.4088/jcp.08m04450.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedAged, 80 and overAntidepressive AgentsAntipsychotic AgentsComorbidityDepressive Disorder, MajorDose-Response Relationship, DrugDrug Therapy, CombinationDrug UtilizationFemaleHospitals, VeteransHumansMaleMiddle AgedUnited StatesUnited States Food and Drug AdministrationVeteransConceptsMajor depressive disorderTreatment of MDDAntipsychotic medicationDepressive disorderService useMental health service useVeterans Affairs patientsUse of antipsychoticsHealth service useComorbid mental illnessDrug Administration approvalLong-term safetyRecent U.S. FoodFirst antipsychoticAntipsychotic dosesAntipsychotic prescriptionsPsychiatric comorbidityComorbid schizophreniaMale genderAdministration approvalVeteran characteristicsMedicationsSchizoaffective disorderAntipsychoticsBipolar disorder
2007
Subsyndromal Depressive Symptoms in Middle-Aged and Older Persons with Schizophrenia
Zisook S, Montross L, Kasckow J, Mohamed S, Palmer BW, Patterson TL, Golshan S, Fellows I, Lehman D, Solorzano E. Subsyndromal Depressive Symptoms in Middle-Aged and Older Persons with Schizophrenia. American Journal Of Geriatric Psychiatry 2007, 15: 1005-1014. PMID: 18056819, DOI: 10.1097/jgp.0b013e3180a725ec.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsChronic DiseaseCitalopramComorbidityDepressionDepressive Disorder, MajorDouble-Blind MethodFemaleFollow-Up StudiesHealth StatusHumansMaleMiddle AgedPlacebosPsychiatric Status Rating ScalesPsychotic DisordersSchizophreniaSchizophrenic PsychologySelective Serotonin Reuptake InhibitorsSuicideTreatment OutcomeConceptsSubsyndromal depressive symptomsDepressive symptomsOlder patientsClinical featuresSchizoaffective disorderNegative symptomsHamilton Depression Rating ScaleImportant clinical dimensionGeneral medical conditionsDepression Rating ScaleSpecific depressive symptomsMental functioningSubstantial morbiditySevere akathisiaMovement abnormalitiesChronic schizophreniaMedical conditionsDepression groupOverall psychopathologyIntervention studiesDepressive symptomatologyPatientsSymptomsOlder personsGeneral psychopathology
2006
Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial
Mohamed S, Osatuke K, Aslam M, Kasckow J. Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial. The American Journal Of Geriatric Pharmacotherapy 2006, 4: 201-209. PMID: 17062320, DOI: 10.1016/j.amjopharm.2006.08.001.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnxiety DisordersCitalopramDepressive Disorder, MajorFemaleHumansMalePilot ProjectsSelective Serotonin Reuptake InhibitorsConceptsMajor depressive disorderComorbid major depressive disorderElderly patientsComorbid depressionEscitalopram 10Adverse eventsPilot trialBaseline Montgomery-Asberg Depression Rating Scale (MADRS) scoreMontgomery-Asberg Depression Rating Scale scoreSecondary efficacy end pointsSelective serotonin reuptake inhibitorsDepression Rating Scale scoresVeterans Affairs Medical CenterEfficacy end pointPrimary efficacy variableMedical Outcomes StudySerotonin reuptake inhibitorsShort-term administrationHAM-A scoresHamilton Rating ScaleLack of efficacyPoor treatment responseRating Scale scoresSymptoms of depressionGreater symptom severity